Beta blockers in patients with end-stage renal disease-Evidence-based recommendations

Seminars in Dialysis
Matthew A Weir, Charles A Herzog

Abstract

For patients who require hemodialysis, beta blockers offer a simultaneous opportunity and challenge in the treatment of cardiovascular disease. Beta blockers are well supported by data from nondialysis populations and directly mitigate the sympathetic overactivity that links chronic kidney disease with cardiovascular sequelae. However, the evidence supporting their use in patients receiving hemodialysis is sparse and the heterogeneity of the beta blocker class makes it difficult to prescribe these medications with confidence. Despite these limitations, both trial and observational data exist that can help guide the use of these medications. In this review, we outline the reasons to consider beta blockers for patients receiving hemodialysis, discuss the barriers to their use, and provide specific evidence-based recommendations for beta blocker use in patients with heart failure, hypertension, ischemic heart disease and arrhythmia.

References

Oct 1, 1978·Canadian Journal of Physiology and Pharmacology·R L KlineP F Mercer
Jan 10, 1993·The New England Journal of Medicine·R L ConverseR G Victor
Apr 1, 1991·Clinical Pharmacokinetics·W H FrishmanG Gorodokin
Feb 1, 1990·Kidney International·P CastellinoR A DeFronzo
Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Jan 1, 1986·American Journal of Nephrology·R A ShermanR P Eisinger
Jan 1, 1984·European Journal of Clinical Pharmacology·J Ladefoged
Nov 1, 1995·Journal of the American College of Cardiology·D M KayeM D Esler
Jan 1, 1997·Physiological Reviews·G F DiBona, U C Kopp
Apr 29, 1999·The New England Journal of Medicine·G LigtenbergH A Koomans
Jun 25, 1999·BMJ : British Medical Journal·N FreemantleJ Harrison
Jul 10, 2002·Hypertension·Carmine ZoccaliUNKNOWN CREED investigators
Aug 15, 2002·American Heart Journal·Peter A McCulloughHarold J Manley
Oct 9, 2002·Circulation·Martin HausbergKarl Heinz Rahn
Oct 10, 2002·Kidney International·Robert N FoleyUNKNOWN United States Renal Data System
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Jan 23, 2003·Journal of the American Society of Nephrology : JASN·Inge H H T KleinPeter J Blankestijn
Mar 8, 2003·Hypertension·Gerald F DiBona
May 14, 2003·Journal of the American College of Cardiology·Gennaro CiceRaffaele Calabrò
May 15, 2003·American Journal of Hypertension·Heinrich HolzgreveHans Uwe Janka
Nov 9, 2004·Lancet·Bo CarlbergLars Hjalmar Lindholm
Nov 13, 2004·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN GEMINI Investigators
Dec 15, 2004·Archives of Internal Medicine·Kevin C AbbottGeorge L Bakris
Mar 15, 2005·European Heart Journal·Magnus PeterssonBengt Rundqvist
Feb 24, 2006·The American Journal of Medicine·Jin H HanW Brian Gibler
Jun 13, 2006·QJM : Monthly Journal of the Association of Physicians·P A Sarafidis, G L Bakris
Oct 6, 2006·Kidney International·G L BakrisE Ritz
Jun 15, 2007·Journal of Hypertension·Oliver ZilchPeter J Blankestijn
Aug 10, 2007·Current Hypertension Reports·Michala E Pedersen, John R Cockcroft

❮ Previous
Next ❯

Citations

Apr 11, 2020·Seminars in Dialysis·Jeffrey H WilliamSylvia E Rosas
Jul 29, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ping-Hsun WuJuan-Jesus Carrero
Jan 1, 2020·The Thoracic and Cardiovascular Surgeon·Yu-Ning HuJun-Neng Roan
Oct 4, 2020·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Hui ZhouSteven J Jacobsen
Apr 4, 2021·Journal of Personalized Medicine·Yi-Ting LinPing-Hsun Wu
Jul 31, 2021·American Journal of Preventive Cardiology·Harold E BaysPeter P Toth
May 1, 2020·American Journal of Preventive Cardiology·Harold Edward Bays

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

The New England Journal of Medicine
R L ConverseR G Victor
Journal of the American Society of Nephrology : JASN
Markus P SchlaichGavin W Lambert
© 2022 Meta ULC. All rights reserved